Acadia Pharmaceuticals (ACAD) PT Raised to $35 at Citi, Opens 90-Day Upside CW
Citi analyst Yigel Nochomovitz raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $35.00 (from $32.00) while maintaining a Buy rating.
- Opens 90-Day Upside Catalyst Watch